Setara launched with $90 million in Series A funding to pursue rare disease genetics at scale after Actio’s acquisition by Jazz Pharmaceuticals. The new company will carry forward Actio’s pipeline under new ownership, including STAR-0871, a small-molecule TRPV4 inhibitor designed for Charcot-Marie-Tooth disease type 2C. Setara also plans to extend the TRPV4 biology toward a broader urology-focused opportunity in overactive bladder, leveraging insights from the rare 2,500-patient population to inform a “one to many” translation hypothesis. The financing underscores how acquired assets are being re-packaged into platform-driven genetics and target-development plays, with investors backing continuity in team and strategy after prior deal activity.